Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Nexvax2 Preceded by a Dose Titration Period in Subjects With Celiac Disease Currently on a Gluten-Free Diet

NCT02528799 is registered in ClinicalTrials.gov with ImmusanT, Inc. as lead sponsor.

NCT NCT02528799
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02528799 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Nexvax2 Preceded by a Dose Titration Period in Subjects With Celiac Disease Currently on a Gluten-Free Diet
Lead sponsor
ImmusanT, Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2015
Completion date
January 6, 2017
Enrollment
38 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

celiac disease